metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - all population
versus Standard of Care (SoC)
	durvalumab plus tremelimumab
	MYSTIC (DT ; all population), 2020 JAMA Oncol 2020 May 1;6(5):661-674. NCT02453282	RCT	mNSCLC - L1 - all population	durvalumab and tremelimumab	platinum-based doublet chemotherapy	first-line treatment of patients locally advanced or metastatic NSCLC with PDL1 TC >=25%	372 / 372	some concern	inconclusive	no statistically significant result
	nivolumab plus ipilimumab plus SoC
	CheckMate 9LA, 2021 Lancet Oncol 2021 Jan 18;S1470-2045(20)30641-0. ESMO Open. 2021 Oct 1 NCT03215706	RCT	mNSCLC - L1 - all population	nivo plus ipi and chemo (2 cycle)	chemotherapy platine combination	patient treated as First Line Therapy in squamous or non-squamous stage IV or recurrentNSCLC	361 / 358	some concern	conclusif	demonstrated 31 % decrease in deaths (OS) (PE) demonstrated 30 % decrease in progression or deaths (PFS) (PE) suggested 34 % decrease in deaths (OS) (extension) suggested 32 % decrease in PFS (extension) more...
mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive
versus pembrolizumab plus placebo
	pembrolizumab plus ipilimumab
	KEYNOTE-598, 2020 J Clin Oncol 2021 Jan 29;JCO2003579. NCT03302234	RCT	mNSCLC - L1 - PDL1 positive	pembrolizumab plus ipilimumab	placebo plus pembrolizumab	as first-line treatment of patients with metastatic NSCLC whose tumors express PD-L1 with a tumor proportion score (TPS) ≥50% and no EGFR or ALK aberrations	284 / 284	low	inconclusive	inconclusive 8 % increase in deaths (OS) (PE) inconclusive 6 % increase in progression or deaths (PFS) (PE)
versus pemetrexed plus platin
	nivolumab plus ipilimumab
	CheckMate 227 (NI vs C ; PDL1>1%), 2018 Eur J Cancer 2019 Jul;116:137-147. N Engl J Med 2018 May 31;378(22):2093-2104. N Engl J Med 2019 Nov 21;381(21):2020-2031. Oncology (Williston Park) 2020 Jul 15;34(7):254. J Thorac Oncol 2021 Apr;16(4):665-676. J Thorac Oncol. 2021 Oct 11;S1556-0864(21)03207-X NCT02477826	RCT	mNSCLC - L1 - PDL1 positive	nivolumab plus ipilimumab	platinium chemotherapy	patients with histologically confirmed squamous or nonsquamous stage IV or recurrent NSCLC who had received no previous systemic anticancer therapy and PDL1>1%	396 / 397	some concern	conclusif	demonstrated 21 % decrease in deaths (OS) (PE) suggested 18 % decrease in progression or deaths (PFS)
versus Standard of Care (SoC)
	durvalumab plus tremelimumab
	MYSTIC (DT ; PDL1>25%), 2020 JAMA Oncol 2020 May 1;6(5):661-674. NCT02453282	RCT	mNSCLC - L1 - PDL1 positive	durvalumab and tremelimumab	platinum-based doublet chemotherapy	first-line treatment of patients locally advanced or metastatic NSCLC with PDL1 TC >=25%	163 / 162	some concern	inconclusive	inconclusive 15 % decrease in deaths (OS) (PE) inconclusive 5 % increase in progression or deaths (PFS) (PE)
mNSCLC - L1 - TMB>10Mb metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - TMB10Mb
versus pemetrexed plus platin
	nivolumab plus ipilimumab
	CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 Eur J Cancer 2019 Jul;116:137-147. N Engl J Med 2018 May 31;378(22):2093-2104. Oncology (Williston Park) 2020 Jul 15;34(7):254. N Engl J Med 2019 Nov 21;381(21):2020-2031. J Thorac Oncol 2021 Apr;16(4):665-676. NCT02477826	RCT	mNSCLC - L1 - TMB>10Mb	nivolumab plus ipilimumab	platinium chemotherapy	patients with histologically confirmed squamous or nonsquamous stage IV or recurrent NSCLC who had received no previous systemic anticancer therapy and TMB > 10mut/Mb	139 / 160	some concern	conclusif	demonstrated 42 % decrease in progression or deaths (PFS) (PE)

Study

study type

Pathology

Patients

sample sizes

ROB

Results

NCT02453282

RCT

mNSCLC - L1 - all population

durvalumab and tremelimumab

platinum-based doublet chemotherapy

first-line treatment of patients locally advanced or metastatic NSCLC with PDL1 TC >=25%

372 / 372

NCT03215706

RCT

mNSCLC - L1 - all population

nivo plus ipi and chemo (2 cycle)

chemotherapy platine combination

patient treated as First Line Therapy in squamous or non-squamous stage IV or recurrentNSCLC

361 / 358

demonstrated 31 % decrease in deaths (OS) (PE)
demonstrated 30 % decrease in progression or deaths (PFS) (PE)
suggested 34 % decrease in deaths (OS) (extension)
suggested 32 % decrease in PFS (extension)

NCT03302234

RCT

mNSCLC - L1 - PDL1 positive

pembrolizumab plus ipilimumab

placebo plus pembrolizumab

as first-line treatment of patients with metastatic NSCLC whose tumors express PD-L1 with a tumor proportion score (TPS) ≥50% and no EGFR or ALK aberrations

284 / 284

inconclusive 8 % increase in deaths (OS) (PE)
inconclusive 6 % increase in progression or deaths (PFS) (PE)

NCT02477826

RCT

mNSCLC - L1 - PDL1 positive

nivolumab plus ipilimumab

platinium chemotherapy

patients with histologically confirmed squamous or nonsquamous stage IV or recurrent NSCLC who had received no previous systemic anticancer therapy and PDL1>1%

396 / 397

demonstrated 21 % decrease in deaths (OS) (PE)
suggested 18 % decrease in progression or deaths (PFS)

NCT02453282

RCT

mNSCLC - L1 - PDL1 positive

durvalumab and tremelimumab

platinum-based doublet chemotherapy

first-line treatment of patients locally advanced or metastatic NSCLC with PDL1 TC >=25%

163 / 162

inconclusive 15 % decrease in deaths (OS) (PE)
inconclusive 5 % increase in progression or deaths (PFS) (PE)

NCT02477826

RCT

mNSCLC - L1 - TMB>10Mb

nivolumab plus ipilimumab

platinium chemotherapy

patients with histologically confirmed squamous or nonsquamous stage IV or recurrent NSCLC who had received no previous systemic anticancer therapy and TMB > 10mut/Mb

139 / 160

demonstrated 42 % decrease in progression or deaths (PFS) (PE)

mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - all population

mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive

mNSCLC - L1 - TMB>10Mb metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - TMB10Mb